Freedom Finance and Binance Join Forces in Digital Assets 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
BOSTON, May 01, 2018 -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 4:10 p.m. ET in Boston.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the selective inhibition of TORC1 - an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac and neurologic systems. RTB101, resTORbio’s lead drug candidate, is a selective, orally administered, TORC1 inhibitor currently being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. The company expects to develop RTB101 for additional aging-related indications such as heart failure or neurodegenerative diseases.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Michael Lampe
Scient PR
484-575-5040
[email protected]
